Skip to main content
Premium Trial:

Request an Annual Quote

OGT, Sanger to Co-develop Prenatal Microarray for Genetic Disorders

NEW YORK (GenomeWeb News) - Oxford Gene Technology and the Wellcome Trust Sanger Institute will work together to develop a microarray to test for prenatal genetic defects, OGT said today.
 
The organizations will co-develop a commercial diagnostic that is expected to be faster and more cost-effective than current prenatal testing methods.
 
Under the agreement, OGT will use its ink jet in-situ synthesis platform to make a 60-mer oligonucleotide microarray, while Sanger will contribute clinical knowledge in targeting “the most appropriate syndromes,” OGT said.
 
OGT’s R&D director, John Anson, said the company is developing numerous products for array comparative genomic hybridization applications that will, with Sanger’s contribution, be used to develop and validate an array “with greater resolution and reproducibility.”

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.